You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
PM 226 New
Potent and selective CB2 receptor agonist (Ki = 12.8 nM; EC50 = 38.67 nM). Exhibits negligible affinity for the CB1 receptor (Ki > 40,000 nM) and no activity at the GPR55. Suppresses neuroinflammation by reducing microglial activation in a multiple sclerosis mouse model. BBB permeable; anti-inflammatory and neuroprotective.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solubility||Soluble in methyl acetate (supplied pre-dissolved -10mg/ml)|
References are publications that support the biological activity of the product.
Navarro et al (2016) Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders. Front. Neurosci. 10 406 PMID: 27679556
Morales et al (2016) Chromenopyrazole, a versatile cannabinoid scaffold with in vivo activity in a model of multiple sclerosis. J.Med.Chem. 59 6753 PMID: 27309150
Gómez-Cañas et al (2016) Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile. Pharmacol.Res. 110 205 PMID: 27013280
If you know of a relevant reference for PM 226, please let us know.
View Related Products by Product Action
Keywords: PM 226, PM 226 supplier, PM226, Potent, selective, CB2, agonists, agonism, BBB, permeable, anti-inflammatory, neuroprotective, cannabinoids, receptors, Receptors, 6220, Tocris Bioscience
Citations for PM 226
Citations are publications that use Tocris products.
Currently there are no citations for PM 226. Do you know of a great paper that uses PM 226 from Tocris? Please let us know.
Reviews for PM 226
There are currently no reviews for this product. Be the first to review PM 226 and earn rewards!
Have you used PM 226?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.